This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the recent FDA approval of Ocrevus Zunovo for the treatment of multiple sclerosis.
Ticker(s): RHHBYWho's the expert?
Institution: UPenn
- Director Emeritus, Multiple Sclerosis Center and Associate Professor of Neurology at the University of Pennsylvania.
- Treats 1500 patients with Multiple Sclerosis.
- Clinical expertise include Multiple Sclerosis (MS), Parkinsons, Myasthenia Gravis and other neuromuscular diseases; Research interest focuses on the development of new compounds for the treatment of multiple sclerosis (MS) and the utilization of new MRI techniques to study MS pathogenesis and immunology.
Interview GoalThis call will feature a discussion on the recent approval of the new formulation Ocrevus Zunovo and an analysis of its pre-approval data.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
